Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALM0124
- Development stage
- Preclinical
- Lead developer
- Alchemedicine
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ALM0124 is a preclinical-stage small molecule drug candidate being developed by Alchemedicine for the treatment of diabetic neuropathy. The program is currently in the preclinical phase of development. Alchemedicine has executed a Material Transfer Agreement (MTA) with an undisclosed partner for the asset, suggesting external interest in its therapeutic potential. While the specific biological target and mechanism of action remain undisclosed by the sponsor, the drug is positioned to address the underlying pathology or symptoms associated with nerve damage in diabetic patients.
- Other names
- ALM0124ALM-0124ALM 0124
Beyond the preview
Go deeper on ALM0124.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALM0124.